Accessibility Menu
Abbott Laboratories Stock Quote

Abbott Laboratories (NYSE: ABT)

$127.83
(0.2%)
+0.29
Price as of October 22, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$127.83
Daily Change
(0.2%) +$0.29
Day's Range
$127.04 - $128.93
Previous Close
$127.83
Open
$127.77
Beta
0.56
Volume
202,496
Average Volume
5,832,726
Market Cap
222B
Market Cap / Employee
$127.54M
52wk Range
$110.86 - $141.23
Revenue
-
Gross Margin
0.58%
Dividend Yield
1.85%
EPS
$8
CAPs Rating
-
Industry
Healthcare Equipment and Supplies

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Abbott Laboratories Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ABT+12.28%+29.92%+5.37%+262,336%
S&P+14.5%+93.32%+14.09%+6,871%

Abbott Laboratories Company Info

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

News & Analysis

The Fool has written over 1,000 articles on Abbott Laboratories.

Financial Health

General

Q3 2025YOY Change
Revenue$11.37B6.9%
Gross Profit$6.34B16.8%
Gross Margin55.75%4.7%
Market Cap$233.12B17.5%
Market Cap / Employee$2.04M0.0%
Employees114K0.0%
Net Income$1.64B0.2%
EBITDA$2.85B14.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$6.95B-0.5%
Accounts Receivable$7.97B16.3%
Inventory7K2.1%

Liabilities

Q2 2025YOY Change
Long Term Debt$12.93B-1.6%
Short Term Debt$507.00M-68.6%

Ratios

Q2 2025YOY Change
Return On Assets17.75%10.2%
Return On Invested Capital13.47%2.9%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$1.55B8.3%
Operating Free Cash Flow$2.05B4.4%

Valuation

MetricQ4 2024Q1 2025Q2 2025Q3 2025YoY Change
Price to Earnings14.7617.2117.0116.75-51.70%
Price to Book4.934.824.854.61-8.62%
Price to Sales4.715.475.525.3410.53%
Price to Tangible Book Value22.3312.8312.3311.27-53.53%
Price to Free Cash Flow TTM73.2578.5284.2284.99-8.46%
Enterprise Value to EBITDA78.9173.3197.5585.7812.61%
Free Cash Flow Yield1.4%1.3%1.2%1.2%9.24%
Return on Equity14.9%31.0%30.7%31.0%114.21%
Total Debt$14.98B$15.28B$13.24B$13.44B-8.93%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.